Spineguard (XPAR:ALSGD) Research & Development: €1.08 Mil (TTM As of Dec. 2025)


What is Spineguard Research & Development?

Spineguard XPAR:ALSGD -2.79% Research & Development is €1.08 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Spineguard's Research & Development for the six months ended in Dec. 2025 was €0.42 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €1.08 Mil.

Spineguard  (XPAR:ALSGD) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Spineguard Research & Development Related Terms

Spineguard Research & Development Historical Data

* Premium members only.

The historical data trend for Spineguard's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spineguard Research & Development Chart

Spineguard Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.79 0.90 1.43 1.29 1.08

Spineguard Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.79 0.85 0.45 0.66 0.42

Spineguard Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €1.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €1.08 Mil mean?
Spineguard (XPAR:ALSGD) has a Research & Development of €1.08 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Spineguard and its competitors.
Is Spineguard's Research & Development too high?
Spineguard's current Research & Development is €1.08 Mil.
How does Spineguard's Research & Development compare to ABT and SYK?
Spineguard's Research & Development of €1.08 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Spineguard and its competitors. Spineguard's current Research & Development is €1.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spineguard stock overvalued right now?
Based on GuruFocus' analysis, Spineguard (XPAR:ALSGD) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.10, compared to a current price of €0.09 — trading 13% below its estimated fair value. The current Research & Development is €1.08 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Spineguard (XPAR:ALSGD), the current Research & Development is €1.08 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Spineguard Business Description

Other Exchanges 6W5:Germany
Address 10 Cours Louis Lumiere, Vincennes, FRA, 94300
Spineguard is engaged in the design and production of medical instruments used for spinal surgeries. It is deploying its proprietary radiation-free real time sensing technology DSG (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. It designs, develops and markets medical devices embedding its technology. The group is developing DSG digital technology for real-time surgical guidance without X-rays to improve the safety and simplify the placement of bone implants, pedicle screws, and smart drills. SpineGuard is extending the applications of its DSG technology to anterior scoliosis treatment, sacroiliac joint fusion, and dental implantology.